Mesenchymal stem cell therapy for cartilage repair - Medipost

Drug Profile

Mesenchymal stem cell therapy for cartilage repair - Medipost

Alternative Names: Cartistem

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medipost
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Osteoarthritis
  • Phase III Knee injuries

Most Recent Events

  • 29 Aug 2017 Medipost completes a phase I/II trial in Osteoarthritis in USA (Intralesional) (NCT01733186)
  • 09 Apr 2015 The product i sitll in phase-III develoment for Knee injuries in South Korea and phase-I/II development for Osteoarthritis in USA
  • 25 Jun 2013 Medipost establishes Medipost Hong Kong to advance its mesenchymal stem cell therapy product in Asian markets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top